Cellect Biotechnology Receives New Patent Allowance in China

Cellect Biotechnology Receives New Patent Allowance in China

Israel, April 2, 2020 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables

the functional selection of stem cells, received an official communication from the China National Intellectual Property Administration

("CNIPA") regarding its intention to grant Chinese Patent Application No. 201380021092.5. Including this latest notification,

the Company has 66 patent applications worldwide, of which 32 are issued/allowed patents.

is just the latest jurisdiction to recognize our innovation as we have sought and received IP protections globally to help safeguard

our inventions," commented Dr. Shai Yarkoni, Chief Executive Officer. "In addition to the clinical trials and business

collaborations that continue to validate our technology, increasing our IP portfolio is a valuable asset that can be monetized

either internally or externally."

has previously published third-party data demonstrating improved 'stemness' of stem cells. Specifically, it significantly improves

both proliferation and functional capabilities of hematopoietic (HSC) and mesenchymal (MSC) stem cells originating from bone marrow,

peripheral blood, umbilical cord and adipose tissue.

covers a device and a kit adapted for selection of cells that are resistant to receptor-mediated apoptosis and a method for using

the device and kit. The device enables simultaneous positive selection for both stem-cells and immune cells which support engraftment

and negative selection for immune cells which induce graft versus host disease (GvHD). The device is designed as a closed

compartment cell selection in simplified setting resulting in a safe, efficacious and affordable solution that currently do not

exist. The present invention further discloses uses for the device.

Cellect Biotechnology Ltd.

Cellect Biotechnology

(NASDAQ: APOP) has developed a breakthrough technology, for the selection of stem cells from any given tissue, that aims

to improve a variety of stem cell-based therapies.

technology is expected to provide researchers, clinical community and pharma companies with the tools to rapidly isolate stem

cells in quantity and quality allowing stem cell-based treatments and procedures in a wide variety of applications in regenerative

medicine. The Company's current clinical trial is aimed at bone marrow transplantations in cancer treatment.

release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements

can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan",

"may", "should", "could", "might", "seek", "target", "will",

"project", "forecast", "continue" or "anticipate" or their negatives or variations of

these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These

forward-looking statements and their implications are based on the current expectations of the management of the Company only

and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described

in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies

do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be

interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results

to differ materially from those described in the forward-looking statements: the Company's history of losses and needs for additional

capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Company's ability

to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; the Company's ability

to obtain regulatory approvals; the Company's ability to obtain favorable pre-clinical and clinical trial results; the Company's

technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients

in the Company's clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects;

the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection

the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without

infringing the intellectual property rights of others; competitive companies, technologies and the Company's industry; unforeseen

scientific difficulties may develop with the Company's technology; and the Company's ability to retain or attract key employees

whose knowledge is essential to the development of its products. Any forward-looking statement in this press release speaks only

as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement,

whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities

laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk

Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2018 filed with

the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov , and in the

Company's periodic filings with the SEC.

Cellect Biotechnology Ltd.

Eyal Leibovitz, Chief Financial Officer